Jan 7 (Reuters) - DexCom Inc ::DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2018 AND PROVIDES INITIAL 2019 OUTLOOK.SEES FY 2019 REVENUE ABOUT $1.175 BILLION TO $1.225 BILLION.FY2019 REVENUE VIEW $1.18 BILLION -- REFINITIV IBES DATA.EXPECTS PRELIMINARY, UNAUDITED REVENUE FOR Q4 ENDED DECEMBER 31, 2018 TO EXCEED $331 MILLION.FOR FISCAL 2018, TOTAL PRELIMINARY, UNAUDITED REVENUE IS EXPECTED TO EXCEED $1.025 BILLION, AN INCREASE OF MORE THAN 42% OVER 2017..Q4 REVENUE VIEW $284.8 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $976.6 MILLION -- REFINITIV IBES DATA.
Full Article
Nov 28 (Reuters) - DexCom Inc ::DEXCOM PRICES OFFERING OF $750.0 MILLION OF 0.75% CONVERTIBLE SENIOR NOTES.DEXCOM INC - PRICES OFFERING OF $750.0 MILLION OF 0.75% CONVERTIBLE SENIOR NOTES DUE 2023.
Full Article
Nov 26 (Reuters) - DexCom Inc ::DEXCOM ANNOUNCES PROPOSED OFFERING OF $750 MILLION OF CONVERTIBLE SENIOR NOTES.DEXCOM - INTENDS TO OFFER, SUBJECT TO MARKET CONDITIONS AND OTHER FACTORS, $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2023.DEXCOM INC - INTENDS TO GRANT INITIAL PURCHASERS OF NOTES A 13-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $100 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES.
Full Article
Nov 20 (Reuters) - Alphabet Holding Company Inc [RIC:RIC:ALHC.UL]::DEXCOM INC - COLLABORATION AND LICENSE AGREEMENT WITH VERILY LIFE SCIENCES SHALL CONTINUE UNTIL DECEMBER 31, 2028.DEXCOM INC - AGREEMENT SHALL BE EXTENDED UNTIL DECEMBER 31, 2033 UPON ACHIEVEMENT OF FIRST REVENUE MILESTONE EVENT & PAYMENT BY CO TO VERILY.
Full Article
Nov 20 (Reuters) - DexCom Inc ::DEXCOM INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED .
Full Article
Nov 20 (Reuters) - DexCom Inc ::DEXCOM AND VERILY AMEND COLLABORATION AND LICENSE AGREEMENT.DEXCOM INC - AMENDMENT INTENDED TO REINFORCE JOINT PRODUCT DEVELOPMENT TARGETS, ACCELERATE DEXCOM'S EFFORTS IN TYPE 2 DIABETES.DEXCOM INC - ROYALTY PAYMENTS SET FORTH IN ORIGINAL AGREEMENT HAVE BEEN ELIMINATED IN AMENDED AGREEMENT.DEXCOM INC - FOCUS SHIFTS TO COMMERCIALIZING SECOND GENERATION OFFERING.DEXCOM INC - WILL MAKE AN INITIAL PAYMENT OF $250 MILLION IN SHARES OF ITS COMMON STOCK.DEXCOM INC - DEXCOM WILL NOT OWE ANY ROYALTIES PURSUANT TO TERMS OF AMENDED AGREEMENT.DEXCOM INC - DEXCOM MAY MAKE UP TO $275 MILLION OF MILESTONE PAYMENTS IN SHARES OF ITS COMMON STOCK.DEXCOM - UNDER AGREEMENT, MILESTONE PAYMENTS OF UP TO $280 MILLION MAY BECOME DUE & PAYABLE BY CO UPON ACHIEVEMENT OF FUTURE PRODUCT LAUNCH, REVENUE MILESTONES.DEXCOM INC - FOR VERILY'S ONDUO FRANCHISE, CO TO BE PREFERRED CGM DEVICE SUPPLIER INTO ONDUO'S TYPE 2 DIABETES MANAGEMENT PROGRAM.DEXCOM INC - DEXCOM AND VERILY HAVE EXPANDED OPTIONS TO COLLABORATE ON DEVELOPMENT OF ADDITIONAL PRODUCTS AND SOFTWARE PERTAINING TO DEXCOM'S PRODUCTS.
Full Article
June 5 (Reuters) - DexCom Inc ::AGAMATRIX - PREVAILING OUTCOME IN RETALIATORY PATENT INFRINGEMENT LAWSUIT BROUGHT BY DEXCOM INC.AGAMATRIX - JUDGE ISSUED ORDER IN MAY ORDERING DEXCOM TO PAY AGAMATRIX ITS COSTS, ATTORNEYS' FEES, EXPENSES DEFENDING AGAINST CASE SINCE AUGUST 1, 2017.AGAMATRIX - FEES CO IS REQUESTING ARE ABOUT $1.4 MILLION.
Full Article
Jan 8 (Reuters) - DexCom Inc ::DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2017 AND PROVIDES INITIAL 2018 OUTLOOK.SEES FY 2018 REVENUE ABOUT $830 MILLION TO $850 MILLION.SEES FY 2017 REVENUE ABOUT $715 MILLION.PRELIMINARY Q4 REVENUE $218 MILLION VERSUS I/B/E/S VIEW $212.6 MILLION .FY2017 REVENUE VIEW $710.2 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $854.6 MILLION -- THOMSON REUTERS I/B/E/S.Q4 REVENUE VIEW $212.7 MILLION -- THOMSON REUTERS I/B/E/S.
Full Article
Nov 21 (Reuters) - Dexcom Inc ::Dexcom announces development agreement with Lilly to integrate Dexcom CGM into connected diabetes ecosystem.Says companies expect to combine Lilly's smart insulin delivery devices and Dexcom CGM.
Full Article
Nov 1 (Reuters) - Dexcom Inc :Dexcom, inc. Reports record third quarter 2017 financial results.Q3 non-gaap loss per share $0.04.Q3 gaap loss per share $0.02.Q3 revenue $184.6 million versus i/b/e/s view $184.2 million.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.
Full Article
Earnings vs. 
Estimates